Document Detail

Pharmacologic expulsive treatment of ureteral calculi.
MedLine Citation:
PMID:  16849614     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the role of nifedipine and the alpha(1)-adrenoreceptor antagonists tamsulosin, terazosin, and doxazosin in the expulsive treatment of ureteral calculi. DATA SOURCES: Literature was searched via MEDLINE (1966-February 2006) with subsequent bibliographic review. MeSH headings included ureteral calculi, nifedipine, doxazosin, and adrenergic alpha-antagonists. Key terms were ureteral calculi, nifedipine, tamsulosin, terazosin, and doxazosin. STUDY SELECTION AND DATA EXTRACTION: Trials evaluating nifedipine, tamsulosin, terazosin, and doxazosin for expulsion of ureteral stones were reviewed. All were published in English-language, peer-reviewed journals. DATA SYNTHESIS: Several trials have evaluated the effects of nifedipine and tamsulosin on ureteral stone passage rates and mean time to stone passage in stones no larger than 15 mm. In 28 day trials, the rates of ureteral stone passage were 35-70% in the control groups compared with 77.1-80% in patients treated with nifedipine and 79.3-100% in patients treated with tamsulosin. Average number of days to stone passage in the control groups was 4.6-20, and the time to stone passage was only 5-9.3 days in patients receiving nifedipine and 2.7-7.9 days in those receiving tamsulosin. The stone passage rates and time to stone passage appeared to be similar in one trial that compared tamsulosin with terazosin and doxazosin. Limited data suggest that these agents may have a role as adjuncts to shock wave lithotripsy. Adverse drug reactions were uncommon. CONCLUSIONS: Nifedipine, tamsulosin, terazosin, and doxazosin are safe and effective options in enhancing ureteral stone expulsion in selected patients with uncomplicated presentations.
Michele A Beach; Laurie S Mauro
Related Documents :
11034774 - Anxiolytics for smoking cessation.
17652504 - Advancing outcome measures for the new era of drug development in cystic fibrosis.
20348494 - Treatment with coartem (artemether-lumefantrine) in papua new guinea.
24789924 - Fabrication of solid collagen nanoparticles using electrospray deposition.
7952794 - Fetal consequences and risks attributed to the use of prescribed and over-the-counter (...
23253474 - The systems containing clays and clay minerals from modified drug release: a review.
Publication Detail:
Type:  Journal Article; Review     Date:  2006-07-18
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  40     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:    2006 Jul-Aug
Date Detail:
Created Date:  2006-08-02     Completed Date:  2007-02-21     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1361-8     Citation Subset:  IM    
College of Pharmacy, University of Toledo, 43606, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic alpha-Antagonists / adverse effects,  therapeutic use*
Calcium Channel Blockers / adverse effects,  therapeutic use
Clinical Trials as Topic
Doxazosin / adverse effects,  therapeutic use
Nifedipine / adverse effects,  therapeutic use*
Prazosin / adverse effects,  analogs & derivatives,  therapeutic use
Receptors, Adrenergic, alpha-1 / antagonists & inhibitors
Sulfonamides / adverse effects,  therapeutic use
Ureteral Calculi / drug therapy*
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Calcium Channel Blockers; 0/Receptors, Adrenergic, alpha-1; 0/Sulfonamides; 106133-20-4/tamsulosin; 19216-56-9/Prazosin; 21829-25-4/Nifedipine; 63590-64-7/Terazosin; 74191-85-8/Doxazosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions.
Next Document:  Adverse drug event reporting in intensive care units: a survey of current practices.